• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

有胰腺炎病史的个体接受 GLP-1 受体激动剂治疗后发生急性胰腺炎的发生率。

The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis.

机构信息

Department of Endocrinology, Cleveland Clinic, Cleveland, OH, USA.

Carolina Health Specialist, Myrtle Beach, SC, USA.

出版信息

Diabetes Res Clin Pract. 2024 Sep;215:111806. doi: 10.1016/j.diabres.2024.111806. Epub 2024 Aug 5.

DOI:10.1016/j.diabres.2024.111806
PMID:39111552
Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been reported to increase the risk of acute pancreatitis (AP). This real-world study did not observe a higher frequency of AP with GLP-1RA exposure in adults with T2D and a prior history of AP regardless of etiology.

摘要

胰高血糖素样肽-1 受体激动剂（GLP-1RA）已被报道会增加急性胰腺炎（AP）的风险。这项真实世界研究未观察到 2 型糖尿病（T2D）合并 AP 既往史的成人在使用 GLP-1RA 后出现 AP 频率更高的情况，无论病因如何。

相似文献

1
The incidence of acute pancreatitis with GLP-1 receptor agonist therapy in individuals with a known history of pancreatitis.有胰腺炎病史的个体接受 GLP-1 受体激动剂治疗后发生急性胰腺炎的发生率。
Diabetes Res Clin Pract. 2024 Sep;215:111806. doi: 10.1016/j.diabres.2024.111806. Epub 2024 Aug 5.
2
Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.胰高血糖素样肽-1 受体激动剂与 2 型糖尿病患者急性胰腺炎风险的关系。
Diabetes Obes Metab. 2017 Jun;19(6):906-908. doi: 10.1111/dom.12885. Epub 2017 Mar 17.
3
No pancreatic safety concern following glucagon-like peptide-1 receptor agonist therapies: A pooled analysis of cardiovascular outcome trials.GLP-1 受体激动剂治疗后无胰腺安全性担忧：心血管结局试验的汇总分析。
Diabetes Metab Res Rev. 2018 Nov;34(8):e3061. doi: 10.1002/dmrr.3061. Epub 2018 Sep 14.
4
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?肠降血糖素类似物与急性胰腺炎：敌是友非？
Curr Opin Gastroenterol. 2024 Sep 1;40(5):404-412. doi: 10.1097/MOG.0000000000001057. Epub 2024 Jul 4.
5
Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.胰高血糖素样肽-1 受体激动剂与糖尿病成人患者心房颤动风险：一项真实世界研究。
J Gen Intern Med. 2024 May;39(7):1112-1121. doi: 10.1007/s11606-023-08589-3. Epub 2024 Jan 8.
6
Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.胰高血糖素样肽-1 受体激动剂（胰腺炎、胰腺癌和胆石症）的安全性问题：来自随机对照试验的数据。
Diabetes Obes Metab. 2017 Sep;19(9):1233-1241. doi: 10.1111/dom.12926. Epub 2017 Jun 20.
7
Association of glucagon-like peptide-1 receptor agonist use and rates of acute myocardial infarction, stroke and overall mortality in patients with type 2 diabetes mellitus in a large integrated health system.在一个大型综合医疗体系中，2 型糖尿病患者使用胰高血糖素样肽-1 受体激动剂与急性心肌梗死、中风和总死亡率的相关性。
Diabetes Obes Metab. 2017 Nov;19(11):1555-1561. doi: 10.1111/dom.12969. Epub 2017 Jul 5.
8
Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.与其他传统抗高血糖药物相比，在二甲双胍的基础上加用肠促胰岛素治疗不会增加胰腺疾病的风险：2 型糖尿病患者的真实世界证据。
Diabet Med. 2019 Apr;36(4):491-498. doi: 10.1111/dme.13835. Epub 2018 Oct 25.
9
Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study.GLP-1 受体激动剂或基础胰岛素起始常规治疗 2 型糖尿病的心血管结局：一项区域范围的回顾性研究。
Cardiovasc Diabetol. 2021 Nov 13;20(1):222. doi: 10.1186/s12933-021-01414-3.
10
GLP-1 receptor agonists and pancreatic safety concerns in type 2 diabetic patients: data from cardiovascular outcome trials.2型糖尿病患者中胰高血糖素样肽-1受体激动剂与胰腺安全性问题：来自心血管结局试验的数据
Endocrine. 2020 Jun;68(3):518-525. doi: 10.1007/s12020-020-02223-6. Epub 2020 Feb 26.

引用本文的文献

1
Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions.胰高血糖素样肽-1受体激动剂：演变、胃肠道不良反应及未来方向。
World J Gastrointest Pharmacol Ther. 2025 Sep 5;16(3):107148. doi: 10.4292/wjgpt.v16.i3.107148.
2
All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium-Glucose Cotransporter-2 Inhibitors.使用胰高血糖素样肽-1受体激动剂与钠-葡萄糖协同转运蛋白-2抑制剂治疗的2型糖尿病成年患者的全因死亡率和胃肠道不良反应
Gastro Hep Adv. 2025 Jul 5;4(10):100736. doi: 10.1016/j.gastha.2025.100736. eCollection 2025.
3
The Impact and Safety of GLP-1 Agents and Breast Cancer.
胰高血糖素样肽-1（GLP-1）受体激动剂与乳腺癌的影响及安全性
Cancer Med. 2025 Jun;14(12):e70932. doi: 10.1002/cam4.70932.
4
Cystic Fibrosis and Hemochromatosis Carriers May Be Prone to Glucagon-like Peptide-1 Agonist Pancreatitis: 3 Cases.囊性纤维化和血色素沉着症携带者可能易患胰高血糖素样肽-1激动剂所致胰腺炎：3例报告
JCEM Case Rep. 2025 May 15;3(7):luaf104. doi: 10.1210/jcemcr/luaf104. eCollection 2025 Jul.
5
New drugs for the treatment of obesity: do we need approaches to preserve muscle mass?治疗肥胖症的新药：我们是否需要采取措施来维持肌肉质量？
Rev Endocr Metab Disord. 2025 May 5. doi: 10.1007/s11154-025-09967-4.
6
A Case of Intussusception With Bowel Obstruction in a Gastric Roux-en-Y Patient Prescribed Semaglutide.一例接受司美格鲁肽治疗的胃 Roux-en-Y 患者发生肠套叠伴肠梗阻的病例
J Am Coll Emerg Physicians Open. 2025 Jan 30;6(2):100045. doi: 10.1016/j.acepjo.2025.100045. eCollection 2025 Apr.
7
Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective.胰高血糖素样肽-1受体激动剂在代谢功能障碍相关脂肪性肝病中的现状：临床视角
J Clin Transl Hepatol. 2025 Jan 28;13(1):47-61. doi: 10.14218/JCTH.2024.00271. Epub 2024 Nov 6.